Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma

Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma

Abstract Background Ex vivo drug screening refers to the out-of-body assessment of drug efficacy in patient derived vital tumor cells. The purpose of these methods is to enable functional testing of patient specific efficacy of anti-cancer therapeutics and personalized treatment strategies. Such app...

Full description

Bibliographic Details
Main Authors: Rami Mäkelä, Antti Arjonen, Ville Härmä, Nina Rintanen, Lauri Paasonen, Tobias Paprotka, Kerstin Rönsch, Teijo Kuopio, Juha Kononen, Juha K. Rantala
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Cancer
Subjects:
Ex vivo drug screening
Urachal carcinoma
Rare cancer
Precision medicine
Online Access:http://link.springer.com/article/10.1186/s12885-020-07092-w

Internet

http://link.springer.com/article/10.1186/s12885-020-07092-w

Similar Items